ICU Medical (NASDAQ:ICUI) Director Elisha Finney Sells 1,700 Shares of Company Stock

ICU Medical, Inc. (NASDAQ:ICUI) Director Elisha Finney sold 1,700 shares of the stock in a transaction on Friday, November 13th. The stock was sold at an average price of $179.00, for a total value of $304,300.00. Following the completion of the sale, the director owned 4,871 shares in the company, valued at approximately $871,909. The trade was a 25.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

ICU Medical Trading Up 0.9%

Shares of ICUI traded up $1.60 during trading hours on Friday, reaching $178.90. 195,454 shares of the company traded hands, compared to its average volume of 283,069. The firm has a market cap of $4.47 billion, a price-to-earnings ratio of 74.85, a PEG ratio of 2.24 and a beta of 0.88. ICU Medical, Inc. has a 12-month low of $113.37 and a 12-month high of $192.85. The company has a current ratio of 2.37, a quick ratio of 1.19 and a debt-to-equity ratio of 0.52. The stock’s fifty day moving average price is $163.46 and its 200 day moving average price is $149.76.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.30. The company had revenue of $556.22 million during the quarter, compared to analyst estimates of $552.03 million. ICU Medical had a net margin of 2.76% and a return on equity of 8.40%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the business posted $2.03 EPS. Sell-side analysts forecast that ICU Medical, Inc. will post 7.22 earnings per share for the current year.

Hedge Funds Weigh In On ICU Medical

A number of large investors have recently added to or reduced their stakes in ICUI. Allworth Financial LP purchased a new stake in shares of ICU Medical during the second quarter valued at about $26,000. Bessemer Group Inc. lifted its position in ICU Medical by 65.8% during the third quarter. Bessemer Group Inc. now owns 189 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 75 shares during the last quarter. Global Retirement Partners LLC boosted its stake in ICU Medical by 203.4% in the third quarter. Global Retirement Partners LLC now owns 179 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 120 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in ICU Medical by 78.4% in the third quarter. Hantz Financial Services Inc. now owns 239 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 105 shares in the last quarter. Finally, Versant Capital Management Inc boosted its stake in ICU Medical by 26.2% in the third quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 65 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ICUI has been the subject of a number of research analyst reports. Raymond James Financial reaffirmed a “strong-buy” rating and set a $200.00 target price on shares of ICU Medical in a research report on Friday, August 7th. KeyCorp raised their price target on ICU Medical from $187.00 to $189.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Piper Sandler lifted their price objective on ICU Medical from $195.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, November 6th. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, BTIG Research increased their target price on shares of ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $195.20.

About ICU Medical

ICU Medical is a medical technology company that develops, manufactures and markets products used in infusion therapy, vascular access and critical care. Its offerings include infusion pumps and related sets and accessories, IV solutions, needlefree connectors, and products designed to help protect healthcare workers when handling hazardous drugs. Founded in 1984, the company expanded its product portfolio through acquisitions, including the infusion systems business of Hospira in 2017 and Smiths Medical in 2022.